Drug-induced aortitis in a patient with ovarian cancer treated with bevacizumab combination therapy
Objective: To review and evaluate drug-induced vasculitis, which is an extremely rare complication of chemotherapy. Case report: A 47-year-old woman with ovarian cancer developed aortitis during bevacizumab combination chemotherapy. Contract-enhanced CT showed concentric thickening of the descending...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Book |
| Published: |
Elsevier,
2018-10-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Objective: To review and evaluate drug-induced vasculitis, which is an extremely rare complication of chemotherapy. Case report: A 47-year-old woman with ovarian cancer developed aortitis during bevacizumab combination chemotherapy. Contract-enhanced CT showed concentric thickening of the descending aorta. Antibiotics were administered, but a repeat CE-CT scan showed no resolution of the aortitis. To treat the aortitis, she was started on oral prednisolone. A subsequent CE-CT scan showed no signs of aortitis. She was thus re-started on a modified chemotherapy regimen. Conclusion: Aortitis should be considered in patients receiving bevacizumab combination therapy who develop persistent fever and upper-abdominal pain. Contrast-enhanced CT is useful for detecting drug-induced aortitis. Keywords: Aortitis, Ovarian cancer, Bevacizumab, G-CSF |
|---|---|
| Item Description: | 1028-4559 10.1016/j.tjog.2018.08.026 |